|
BE759838A
(fr)
|
1969-12-04 |
1971-06-03 |
Wellcome Found |
Cetones a activite biologique
|
|
US3885046A
(en)
|
1969-12-04 |
1975-05-20 |
Burroughs Wellcome Co |
Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
|
|
US3942641A
(en)
|
1972-05-05 |
1976-03-09 |
Syntex Corporation |
Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
|
|
US4089855A
(en)
|
1976-04-23 |
1978-05-16 |
Cornell Research Foundation, Inc. |
Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby
|
|
US4218433A
(en)
|
1977-03-03 |
1980-08-19 |
Nippon Kayaku Kabushiki Kaisha |
Constant-rate eluting tablet and method of producing same
|
|
US4217353A
(en)
|
1978-05-19 |
1980-08-12 |
E. I. Du Pont De Nemours And Company |
Method for inducing anorexia
|
|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
|
IL58649A
(en)
|
1978-11-10 |
1982-04-30 |
Beecham Group Ltd |
Pharmaceutical dispensing container
|
|
JPS58134019A
(ja)
|
1982-02-05 |
1983-08-10 |
Ono Pharmaceut Co Ltd |
プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
|
|
JPS59500418A
(ja)
|
1982-03-16 |
1984-03-15 |
ザ ロツクフエラ− ユニバ−シテイ |
胃腸能動作用障害を回復する方法
|
|
US4513006A
(en)
|
1983-09-26 |
1985-04-23 |
Mcneil Lab., Inc. |
Anticonvulsant sulfamate derivatives
|
|
US4689332A
(en)
|
1984-04-09 |
1987-08-25 |
Research Corporation |
Growth regulation and related applications of opioid antagonists
|
|
US5266574A
(en)
|
1984-04-09 |
1993-11-30 |
Ian S. Zagon |
Growth regulation and related applications of opioid antagonists
|
|
US4673679A
(en)
|
1986-05-14 |
1987-06-16 |
E. I. Du Pont De Nemours And Company |
Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
|
|
GB8613689D0
(en)
|
1986-06-05 |
1986-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
|
US4895845A
(en)
|
1986-09-15 |
1990-01-23 |
Seed John C |
Method of assisting weight loss
|
|
NL8800823A
(nl)
|
1987-04-10 |
1988-11-01 |
Sandoz Ag |
Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.
|
|
PH23901A
(en)
|
1987-05-04 |
1989-12-18 |
Lilly Co Eli |
Treatment of diabetes using fluoxetine
|
|
US5000886A
(en)
|
1987-05-26 |
1991-03-19 |
American Cyanamid Company |
Silicone-hardened pharmaceutical microcapsules and process of making the same
|
|
US5364841A
(en)
|
1988-01-11 |
1994-11-15 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and essential hypertension and related disorders
|
|
US4831031A
(en)
|
1988-01-22 |
1989-05-16 |
Pfizer Inc. |
Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
|
|
US5719197A
(en)
|
1988-03-04 |
1998-02-17 |
Noven Pharmaceuticals, Inc. |
Compositions and methods for topical administration of pharmaceutically active agents
|
|
US5202128A
(en)
|
1989-01-06 |
1993-04-13 |
F. H. Faulding & Co. Limited |
Sustained release pharmaceutical composition
|
|
US5114976A
(en)
|
1989-01-06 |
1992-05-19 |
Norden Michael J |
Method for treating certain psychiatric disorders and certain psychiatric symptoms
|
|
EP0483152A4
(en)
|
1989-05-09 |
1992-12-02 |
Whitby Research Incorporated |
A method of reducing body weight and food intake using a dopamine d2 receptor agonist
|
|
DK469989D0
(da)
|
1989-09-22 |
1989-09-22 |
Bukh Meditec |
Farmaceutisk praeparat
|
|
ES2062310T3
(es)
|
1989-12-06 |
1994-12-16 |
Akzo Nv |
Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
|
|
FR2657350B1
(fr)
|
1990-01-19 |
1992-05-15 |
Centre Nat Rech Scient |
Composes destines a l'encapsulation dans les erythrocytes - nouveaux derives de la naloxone et naltrexone.
|
|
US5028612A
(en)
|
1990-03-22 |
1991-07-02 |
Hillel Glover |
Method for treating emotional numbness
|
|
US5213807A
(en)
|
1990-05-03 |
1993-05-25 |
Chemburkar Pramod B |
Pharmaceutical composition containing ibuprofen and a prostaglandin
|
|
US5486362A
(en)
|
1991-05-07 |
1996-01-23 |
Dynagen, Inc. |
Controlled, sustained release delivery system for treating drug dependency
|
|
US5403595A
(en)
|
1991-05-07 |
1995-04-04 |
Dynagen, Inc. |
Controlled, sustained release delivery system for smoking cessation
|
|
DE4136215A1
(de)
|
1991-11-02 |
1993-05-06 |
Ferring Arzneimittel Gmbh, 2300 Kiel, De |
Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
|
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
|
US5312925A
(en)
|
1992-09-01 |
1994-05-17 |
Pfizer Inc. |
Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
|
|
IT1255522B
(it)
|
1992-09-24 |
1995-11-09 |
Ubaldo Conte |
Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
|
|
IT1256393B
(it)
|
1992-11-17 |
1995-12-04 |
Inverni Della Beffa Spa |
Forme matriciali multistrato per il rilascio controllato di principi attivi
|
|
US5512593A
(en)
|
1993-03-02 |
1996-04-30 |
John S. Nagle |
Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
|
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
|
US6183778B1
(en)
|
1993-09-21 |
2001-02-06 |
Jagotec Ag |
Pharmaceutical tablet capable of liberating one or more drugs at different release rates
|
|
IT1265240B1
(it)
|
1993-11-30 |
1996-10-31 |
Ekita Investments Nv |
Compressa farmaceutica a rilascio controllato, di forma lenticolare
|
|
DK0782445T3
(da)
|
1994-09-19 |
2002-05-06 |
Bristol Myers Squibb Pharma Co |
Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed
|
|
US5627187A
(en)
*
|
1995-04-12 |
1997-05-06 |
Katz; Bruce E. |
5-FU for treating actinic kerotoses
|
|
US5714519A
(en)
|
1995-06-07 |
1998-02-03 |
Ergo Science Incorporated |
Method for regulating glucose metabolism
|
|
WO1997006787A2
(en)
|
1995-08-17 |
1997-02-27 |
Dyer, Alison, Margaret |
Controlled release products
|
|
GB9517062D0
(en)
|
1995-08-18 |
1995-10-25 |
Scherer Ltd R P |
Pharmaceutical compositions
|
|
PT914097E
(pt)
|
1996-03-12 |
2002-06-28 |
Alza Corp |
Composicao e forma de dosagem compreendendo antagonista de opioide
|
|
CA2220768A1
(en)
|
1996-03-13 |
1997-09-18 |
Yale University |
Smoking cessation treatments using naltrexone and related compounds
|
|
EP0795327A1
(en)
|
1996-03-13 |
1997-09-17 |
Pfizer Inc. |
Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
|
|
US5716976A
(en)
|
1996-03-13 |
1998-02-10 |
Bernstein; Richard K. |
Method of treatment for carbohydrate addiction
|
|
DE69736928T2
(de)
|
1996-05-07 |
2007-06-28 |
Pliva Istrazivanje I Razvoj D.O.O. |
Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
|
|
IL121076A
(en)
|
1996-06-19 |
2000-10-31 |
Akzo Nobel Nv |
Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
|
|
US6087386A
(en)
|
1996-06-24 |
2000-07-11 |
Merck & Co., Inc. |
Composition of enalapril and losartan
|
|
EP0915697B1
(en)
|
1996-06-28 |
2002-09-18 |
Ortho-McNeil Pharmaceutical, Inc. |
Anticonvulsant sulfamate derivatives useful in treating obesity
|
|
US5878750A
(en)
|
1996-11-14 |
1999-03-09 |
Clemens; Anton H. |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
|
FR2758723B1
(fr)
|
1997-01-28 |
1999-04-23 |
Sanofi Sa |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
|
CA2216215A1
(en)
|
1997-04-05 |
1998-10-05 |
Isa Odidi |
Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
|
|
WO1999007342A1
(en)
|
1997-08-11 |
1999-02-18 |
Alza Corporation |
Prolonged release active agent dosage form adapted for gastric retention
|
|
US6622036B1
(en)
|
2000-02-09 |
2003-09-16 |
Cns Response |
Method for classifying and treating physiologic brain imbalances using quantitative EEG
|
|
AU750808B2
(en)
|
1997-10-03 |
2002-07-25 |
Cary Medical Corporation |
Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
|
|
US6652882B1
(en)
|
1997-10-06 |
2003-11-25 |
Intellipharmaceutics Corp |
Controlled release formulation containing bupropion
|
|
US6262049B1
(en)
|
1997-10-28 |
2001-07-17 |
Schering Corporation |
Method of reducing nicotine and tobacco craving in mammals
|
|
IL127497A
(en)
|
1997-12-18 |
2002-07-25 |
Pfizer Prod Inc |
Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
|
|
US6342515B1
(en)
|
1997-12-26 |
2002-01-29 |
Dainippon Pharmaceutical Co., Ltd. |
Remedy for neurodegenerative diseases
|
|
IL137346A0
(en)
|
1998-01-21 |
2001-07-24 |
Glaxo Group Ltd |
Pharmaceutically active morpholinol
|
|
EP1051167A1
(en)
|
1998-01-29 |
2000-11-15 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (-) -bupropion
|
|
US6048322A
(en)
|
1998-04-15 |
2000-04-11 |
Kushida; Clete |
Morphometric measurement tool
|
|
US6153223A
(en)
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
|
US6150366A
(en)
|
1998-06-15 |
2000-11-21 |
Pfizer Inc. |
Ziprasidone formulations
|
|
US8236352B2
(en)
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
|
US6096341A
(en)
|
1998-10-30 |
2000-08-01 |
Pharma Pass Llc |
Delayed release tablet of bupropion hydrochloride
|
|
US6033686A
(en)
|
1998-10-30 |
2000-03-07 |
Pharma Pass Llc |
Controlled release tablet of bupropion hydrochloride
|
|
EP1005863A1
(en)
|
1998-12-04 |
2000-06-07 |
Synthelabo |
Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
|
|
US20030144174A1
(en)
|
1998-12-09 |
2003-07-31 |
Miles B. Brennan |
Methods for identifying compounds useful for the regulation of body weight and associated conditions
|
|
US6238697B1
(en)
|
1998-12-21 |
2001-05-29 |
Pharmalogix, Inc. |
Methods and formulations for making bupropion hydrochloride tablets using direct compression
|
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
|
US6635281B2
(en)
|
1998-12-23 |
2003-10-21 |
Alza Corporation |
Gastric retaining oral liquid dosage form
|
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
|
CA2364949A1
(en)
|
1999-02-24 |
2000-08-31 |
University Of Cincinnati |
Use of sulfamate derivatives for treating impulse control disorders
|
|
US6210716B1
(en)
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
|
US20030035840A1
(en)
|
2001-02-08 |
2003-02-20 |
Boyong Li |
Controlled release oral dosage form
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
US8545880B2
(en)
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
|
US6589553B2
(en)
|
2001-02-08 |
2003-07-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral dosage form
|
|
US6337328B1
(en)
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
|
US6387956B1
(en)
|
1999-03-24 |
2002-05-14 |
University Of Cincinnati |
Methods of treating obsessive-compulsive spectrum disorders
|
|
MXPA01009893A
(es)
|
1999-04-01 |
2003-07-28 |
Esperion Therapeutics Inc |
Compuestos con eter, composiciones y usos de estos.
|
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
|
PL350924A1
(en)
|
1999-04-06 |
2003-02-10 |
Sepracor Inc |
Derivatives of venlafaxine and methods of preparing and using the same
|
|
NZ514811A
(en)
|
1999-04-08 |
2005-01-28 |
Ortho Mcneil Pharm Inc |
Anticonvulsant derivatives useful in reducing blood glucose levels
|
|
GB9908921D0
(en)
|
1999-04-19 |
1999-06-16 |
Britannia Pharmaceuticals Ltd |
Spray dispenser for opiod antagonists
|
|
US6420369B1
(en)
|
1999-05-24 |
2002-07-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating dementia
|
|
ES2291215T3
(es)
|
1999-06-14 |
2008-03-01 |
Vivus, Inc. |
Terapia de combinacion para producir perdida de peso y tratar la obesidad.
|
|
US7056890B2
(en)
|
1999-06-14 |
2006-06-06 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
|
DE19927688A1
(de)
|
1999-06-17 |
2000-12-21 |
Gruenenthal Gmbh |
Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
|
|
US20040115134A1
(en)
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
|
DE60035232T2
(de)
|
1999-07-01 |
2008-02-14 |
Pharmacia & Upjohn Co. Llc, Kalamazoo |
(S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
|
|
US6071918A
(en)
|
1999-07-21 |
2000-06-06 |
Dupont Pharmaceuticals Company |
Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
|
|
US6500459B1
(en)
|
1999-07-21 |
2002-12-31 |
Harinderpal Chhabra |
Controlled onset and sustained release dosage forms and the preparation thereof
|
|
US6387403B1
(en)
|
1999-09-15 |
2002-05-14 |
Alza Corporation |
Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
|
|
US6489350B1
(en)
|
1999-09-15 |
2002-12-03 |
Elan Pharmaceuticals, Inc. |
Methods for treating neuropathic pain using heteroarylmethanesulfonamides
|
|
US6403657B1
(en)
|
1999-10-04 |
2002-06-11 |
Martin C. Hinz |
Comprehensive pharmacologic therapy for treatment of obesity
|
|
GB2355191A
(en)
|
1999-10-12 |
2001-04-18 |
Laxdale Ltd |
Combination formulations for fatigue, head injury and strokes
|
|
US6410736B1
(en)
|
1999-11-29 |
2002-06-25 |
Pfizer Inc. |
Biaryl ether derivatives useful as monoamine reuptake inhibitors
|
|
WO2001026641A2
(en)
|
1999-10-13 |
2001-04-19 |
Glaxo Group Limited |
Morpholinol derivatives for the treatment of obesity
|
|
AR031682A1
(es)
|
1999-11-19 |
2003-10-01 |
Reckitt Benckiser Helthcare Uk |
Composiciones farmaceuticas
|
|
GB0001449D0
(en)
|
2000-01-21 |
2000-03-08 |
Cortendo Ab |
Compositions
|
|
US20020055512A1
(en)
|
2000-01-21 |
2002-05-09 |
Cortendo Ab. |
Compositions for delivery of a cortisol antagonist
|
|
WO2001052851A1
(en)
|
2000-01-22 |
2001-07-26 |
Albert Shulman |
Methods for the treatment of substance abuse
|
|
CA2397726A1
(en)
|
2000-01-22 |
2001-07-26 |
Albert Shulman |
Methods for the treatment of substance abuse
|
|
US20020090615A1
(en)
|
2000-01-31 |
2002-07-11 |
Rosen Craig A. |
Nucleic acids, proteins, and antibodies
|
|
EP2517710B1
(en)
|
2000-02-08 |
2015-03-25 |
Euro-Celtique S.A. |
Tamper-resistant oral opioid agonist formulations
|
|
US6627223B2
(en)
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
|
CA2403252A1
(en)
|
2000-03-15 |
2001-09-20 |
Wolfgang Sadee |
Neutral antagonists and use thereof in treating drug abuse
|
|
WO2001068104A1
(en)
|
2000-03-16 |
2001-09-20 |
The Mclean Hospital Corporation |
Compounds for the treatment of psychiatric or substance abuse disorders
|
|
US6437147B1
(en)
|
2000-03-17 |
2002-08-20 |
Novo Nordisk |
Imidazole compounds
|
|
AU5066101A
(en)
|
2000-04-13 |
2001-10-30 |
Synthon B.V. |
Modified release formulations containing a hypnotic agent
|
|
US6761895B2
(en)
|
2000-04-17 |
2004-07-13 |
Yamanouchi Pharmaceutical Co., Ltd. |
Drug delivery system for averting pharmacokinetic drug interaction and method thereof
|
|
JPWO2001078681A1
(ja)
|
2000-04-17 |
2004-01-08 |
山之内製薬株式会社 |
薬物動態学的な薬物相互作用を回避する薬物送達システム及びその方法
|
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
|
WO2001085257A2
(en)
|
2000-05-05 |
2001-11-15 |
Pain Therapeutics, Inc. |
Opioid antagonist compositions and dosage forms
|
|
US20020044962A1
(en)
|
2000-06-06 |
2002-04-18 |
Cherukuri S. Rao |
Encapsulation products for controlled or extended release
|
|
US6191117B1
(en)
|
2000-07-10 |
2001-02-20 |
Walter E. Kozachuk |
Methods of producing weight loss and treatment of obesity
|
|
CA2417304A1
(en)
|
2000-08-02 |
2002-02-07 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful for the treatment of depression
|
|
US6528520B2
(en)
|
2000-08-15 |
2003-03-04 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
|
PT1326630E
(pt)
|
2000-09-18 |
2008-09-02 |
Sanos Bioscience As |
Utilização de péptidos glp-2
|
|
ATE334718T1
(de)
|
2000-10-30 |
2006-08-15 |
Ortho Mcneil Pharm Inc |
Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
|
|
US6569449B1
(en)
|
2000-11-13 |
2003-05-27 |
University Of Kentucky Research Foundation |
Transdermal delivery of opioid antagonist prodrugs
|
|
JP2004527553A
(ja)
|
2001-04-26 |
2004-09-09 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療
|
|
EP1262196A3
(en)
|
2001-05-23 |
2002-12-18 |
Pfizer Products Inc. |
Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
|
|
US6960357B2
(en)
|
2001-05-25 |
2005-11-01 |
Mistral Pharma Inc. |
Chemical delivery device
|
|
PT1411900E
(pt)
|
2001-06-01 |
2010-10-11 |
Pozen Inc |
Composições farmacêuticas para a entrega coordenada de aines
|
|
WO2002100382A2
(en)
|
2001-06-08 |
2002-12-19 |
Endo Pharmaceuticals, Inc. |
Controlled release dosage forms using acrylic polymer, and process for making the same
|
|
US6462237B1
(en)
|
2001-06-14 |
2002-10-08 |
Usv Limited |
Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
|
|
WO2003013479A1
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Compositions and methods to prevent abuse of opioids
|
|
MXPA04001210A
(es)
|
2001-08-06 |
2004-07-08 |
Euro Celtique Sa |
Formulaciones de agonista opioide con antagonista liberable y aislado.
|
|
US7842307B2
(en)
|
2001-08-06 |
2010-11-30 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
|
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
|
US20030087896A1
(en)
|
2001-08-09 |
2003-05-08 |
Hillel Glover |
Treatment of refractory depression with an opiate antagonist and an antidepressant
|
|
US20030044462A1
(en)
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
|
US6576256B2
(en)
|
2001-08-28 |
2003-06-10 |
The Brigham And Women's Hospital, Inc. |
Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
ITFI20010230A1
(it)
|
2001-11-29 |
2003-05-29 |
Menarini Int Operations Lu Sa |
Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
|
|
US20030133982A1
(en)
|
2001-12-20 |
2003-07-17 |
Heimlich John M. |
Zero-order sustained release dosage forms and method of making same
|
|
US20040102440A1
(en)
|
2002-07-01 |
2004-05-27 |
Wong Erik Ho Fong |
Method of promoting smoking cessation
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
US20040029941A1
(en)
|
2002-05-06 |
2004-02-12 |
Jennings Julianne E. |
Zonisamide use in obesity and eating disorders
|
|
CN101310723A
(zh)
|
2002-05-17 |
2008-11-26 |
迪欧加药品公司 |
有效的选择性阿片受体调制剂化合物的用途
|
|
JP4545584B2
(ja)
|
2002-05-17 |
2010-09-15 |
デューク ユニバーシティ |
肥満を治療するための方法
|
|
US20050215552A1
(en)
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
|
US20040005368A1
(en)
*
|
2002-07-01 |
2004-01-08 |
Morris Mann |
Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
|
|
US6972291B2
(en)
|
2002-07-02 |
2005-12-06 |
Bernstein Richard K |
Method for reducing food intake
|
|
CA2492488A1
(en)
|
2002-07-16 |
2004-01-22 |
Elan Pharma International, Ltd. |
Liquid dosage compositions of stable nanoparticulate active agents
|
|
EP1534074A4
(en)
|
2002-07-18 |
2008-01-09 |
Merck & Co Inc |
COMBINATION THERAPY FOR THE TREATMENT OF FATIBILITY
|
|
US7086532B2
(en)
|
2003-07-16 |
2006-08-08 |
Allergan, Inc. |
Titration/compliance pack with increasing doses
|
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
US6702097B1
(en)
|
2002-09-04 |
2004-03-09 |
Owens-Brockway Glass Container Inc. |
Method of and apparatus for transferring articles from a fixed position to a moving conveyor
|
|
ES2355723T3
(es)
|
2002-09-11 |
2011-03-30 |
Elan Pharma International Limited |
Composiciones de agente activo en nanopartículas estabilizadas en gel.
|
|
AU2003283958A1
(en)
|
2002-09-13 |
2004-04-30 |
Elan Pharmaceuticals, Inc. |
Method of treating tremors
|
|
WO2004032980A1
(en)
|
2002-10-04 |
2004-04-22 |
Elan Pharma International Limited |
Gamma irradiation of solid nanoparticulate active agents
|
|
US20040092504A1
(en)
|
2002-11-12 |
2004-05-13 |
Anuthep Benja-Athon |
Definitive medications for treating fibromyalgia
|
|
US6893660B2
(en)
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
|
US20040122033A1
(en)
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
|
US20040115265A1
(en)
|
2002-12-11 |
2004-06-17 |
Loutfy Benkerrour |
Multilayered tablet containing pravastatin and aspirin and method
|
|
AU2003296672A1
(en)
|
2002-12-13 |
2004-07-09 |
Cilag Ag |
Controlled release preparations comprising tramadol and topiramate
|
|
CA2414500A1
(en)
|
2002-12-17 |
2004-06-17 |
Purepharm Inc. |
Agonist-aversive combination medicines
|
|
EP1575566B1
(en)
|
2002-12-26 |
2012-02-22 |
Pozen, Inc. |
Multilayer dosage forms containing naproxen and triptans
|
|
US20040185097A1
(en)
|
2003-01-31 |
2004-09-23 |
Glenmark Pharmaceuticals Ltd. |
Controlled release modifying complex and pharmaceutical compositions thereof
|
|
US20040192715A1
(en)
|
2003-02-05 |
2004-09-30 |
Mark Chasin |
Methods of administering opioid antagonists and compositions thereof
|
|
US20040158194A1
(en)
|
2003-02-06 |
2004-08-12 |
Wolff Andy And Beiski Ben Z. |
Oral devices and methods for controlled drug release
|
|
US20040204472A1
(en)
*
|
2003-03-04 |
2004-10-14 |
Pharmacia Corporation |
Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
|
|
EP1772147A2
(en)
|
2003-03-17 |
2007-04-11 |
Japan Tobacco, Inc. |
Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
|
|
WO2004087175A1
(en)
|
2003-04-04 |
2004-10-14 |
Pharmacia Corporation |
Oral extended release compressed tablets of multiparticulates
|
|
EP1613324A2
(en)
|
2003-04-14 |
2006-01-11 |
Pain Therapeutics, Inc. |
Methods for the treatment of pain comprising opioid antagonists
|
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
|
RU2350327C2
(ru)
|
2003-04-29 |
2009-03-27 |
Ориксиджен Серапьютикс, Инкорпорэйтд |
Составы, вызывающие потерю веса
|
|
EP1626722A1
(en)
|
2003-05-16 |
2006-02-22 |
Pfizer Products Inc. |
Method for enhancing cognition using ziprasidone
|
|
EP1633400A2
(en)
|
2003-05-16 |
2006-03-15 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
|
|
US20070099884A1
(en)
|
2003-06-06 |
2007-05-03 |
Erondu Ngozi E |
Combination therapy for the treatment of diabetes
|
|
US20060160834A1
(en)
|
2003-06-06 |
2006-07-20 |
Fong Tung M |
Combination therapy for the treatment of hypertension
|
|
WO2005000217A2
(en)
|
2003-06-06 |
2005-01-06 |
Merck & Co., Inc. |
Combination therapy for the treatment of dyslipidemia
|
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
|
US20050019385A1
(en)
|
2003-07-21 |
2005-01-27 |
Noven Pharmaceuticals, Inc. |
Composition and method for controlling drug delivery from silicone adhesive blends
|
|
US7759358B2
(en)
|
2003-07-23 |
2010-07-20 |
Crooks Peter A |
Oral bioavailable prodrugs
|
|
US20050026966A1
(en)
|
2003-07-30 |
2005-02-03 |
Agouron Pharmaceuticals, Inc. |
Process and chiral amine intermediates useful for preparation of antiproliferative 2,4-diaminothiazole amide compounds
|
|
ES2318330T3
(es)
|
2003-08-08 |
2009-05-01 |
Elan Pharma International Limited |
Nuevas composiciones de metaxalona.
|
|
RS51934B
(sr)
|
2003-08-08 |
2012-02-29 |
Biovail Laboratories International Srl. |
Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
|
|
KR100965580B1
(ko)
*
|
2003-08-21 |
2010-06-23 |
엘지디스플레이 주식회사 |
액정표시장치와 그의 구동방법
|
|
AU2004266043B2
(en)
|
2003-08-21 |
2007-09-20 |
Duchesnay Inc. |
Micronutrient supplement
|
|
US20050043773A1
(en)
|
2003-08-21 |
2005-02-24 |
Ivan Lieberburg |
Methods of improving the safety of zonisamide therapy
|
|
US20050043705A1
(en)
|
2003-08-21 |
2005-02-24 |
Eisai Co., Ltd. |
Methods of using zonisamide as an adjunctive therapy for partial seizures
|
|
US20050043704A1
(en)
|
2003-08-21 |
2005-02-24 |
Eisai Co., Ltd |
Methods of using zonisamide as an adjunctive therapy for partial seizures
|
|
CA2539027C
(en)
|
2003-09-25 |
2010-02-23 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
|
US20050112198A1
(en)
|
2003-10-27 |
2005-05-26 |
Challapalli Prasad V. |
Bupropion formulation for sustained delivery
|
|
US20050096311A1
(en)
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
|
US20050147664A1
(en)
|
2003-11-13 |
2005-07-07 |
Elan Pharma International Ltd. |
Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
|
|
US20070149451A1
(en)
|
2003-11-17 |
2007-06-28 |
Holmes David G |
Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
|
|
WO2005049043A1
(en)
|
2003-11-18 |
2005-06-02 |
Ortho-Mcneil Pharmaceutical, Inc. |
Combination therapy comprising metformin and anticonvulsant agents
|
|
US20050181049A1
(en)
|
2003-11-19 |
2005-08-18 |
Dong Liang C. |
Composition and method for enhancing bioavailability
|
|
UY28650A1
(es)
*
|
2003-12-05 |
2005-02-28 |
Forest Laboratories |
Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
|
|
US20050232990A1
(en)
|
2003-12-31 |
2005-10-20 |
Garth Boehm |
Donepezil formulations
|
|
US7429580B2
(en)
|
2004-01-13 |
2008-09-30 |
Orexigen Therapeutics, Inc. |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
|
US7713959B2
(en)
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
|
US20060160750A1
(en)
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
|
GB0401542D0
(en)
|
2004-01-24 |
2004-02-25 |
Jenner Simon J |
A method of producing a mould
|
|
WO2005079773A2
(en)
|
2004-02-13 |
2005-09-01 |
Neuromolecular, Inc. |
Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
|
|
SE0400378D0
(sv)
|
2004-02-17 |
2004-02-17 |
Jan Hedner |
Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
|
|
US20050214371A1
(en)
|
2004-03-03 |
2005-09-29 |
Simona Di Capua |
Stable pharmaceutical composition comprising an acid labile drug
|
|
US20050245541A1
(en)
|
2004-03-19 |
2005-11-03 |
Elliot Ehrich |
Methods for treating alcoholism
|
|
US20060100205A1
(en)
|
2004-04-21 |
2006-05-11 |
Eckard Weber |
Compositions for affecting weight loss
|
|
BRPI0510593A
(pt)
|
2004-05-03 |
2007-11-20 |
Univ Duke |
composições para afetar a perda de peso
|
|
US20050250838A1
(en)
|
2004-05-04 |
2005-11-10 |
Challapalli Prasad V |
Formulation for sustained delivery
|
|
JP2008509142A
(ja)
|
2004-08-03 |
2008-03-27 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
体重減少に影響を及ぼすためのブプロピオンと第２の化合物との組合せ
|
|
DE602005020462D1
(de)
|
2004-08-25 |
2010-05-20 |
Essentialis Inc |
Pharmazeutische formulierungen von kalium-atp-kanalöffnern und deren verwendungen
|
|
JP2008514612A
(ja)
|
2004-09-23 |
2008-05-08 |
ミシャロウ、アレクサンダー |
対抗適応を誘発することにより神経伝達物質系を調節する方法
|
|
AU2005302669A1
(en)
|
2004-10-27 |
2006-05-11 |
Neurogen Corporation |
Diaryl ureas as CB1 antagonists
|
|
AU2005305140A1
(en)
|
2004-11-04 |
2006-05-18 |
Neurogen Corporation |
Arylalkyl ureas as CB1 antagonists
|
|
EP1827450A4
(en)
|
2004-11-17 |
2009-04-22 |
Cypress Bioscience Inc |
METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
|
|
US20060150989A1
(en)
*
|
2005-01-12 |
2006-07-13 |
Peter Migaly |
Method of diagnosing, treating and educating individuals with and/or about depression
|
|
JP2006232675A
(ja)
|
2005-02-22 |
2006-09-07 |
Kowa Co |
複合型口腔内溶解用固形製剤
|
|
EP1871762A2
(en)
|
2005-04-18 |
2008-01-02 |
Neurogen Corporation |
Subtituted heteroaryl cb1 antagonists
|
|
US20060246131A1
(en)
|
2005-04-28 |
2006-11-02 |
Cottlingham Elizabeth M |
Use of metformin to counteract weight gain associated with psychotropic medications
|
|
AU2006252708A1
(en)
|
2005-05-31 |
2006-12-07 |
Orexigen Therapeutics, Inc. |
Methods and compositions for managing psychotic disorders
|
|
WO2007012064A2
(en)
|
2005-07-20 |
2007-01-25 |
Cypress Bioscience, Inc. |
Prevention and treatment of hearing disorders
|
|
BRPI0613911A2
(pt)
|
2005-07-27 |
2011-02-22 |
Orexigen Therapeutics Inc |
composições para afetar a perda de peso
|
|
DK1971362T3
(en)
|
2005-08-19 |
2015-01-26 |
Amylin Pharmaceuticals Llc |
Exendin for treating diabetes and reducing body weight
|
|
WO2007047351A2
(en)
|
2005-10-13 |
2007-04-26 |
Orexigen Therapeutics, Inc. |
Methods for treating hypertension in overweight and obese individuals
|
|
US20070099947A1
(en)
|
2005-11-03 |
2007-05-03 |
Alkermes, Inc. |
Methods and compositions for the treatment of brain reward system disorders by combination therapy
|
|
EP1951212A2
(en)
|
2005-11-22 |
2008-08-06 |
Orexigen Therapeutics, Inc. |
Compositions and methods for increasing insulin sensitivity
|
|
WO2007089318A2
(en)
|
2005-11-23 |
2007-08-09 |
Orexigen Therapeutics, Inc. |
Compositions and methods for reducing food cravings
|
|
TW200803901A
(en)
|
2005-11-28 |
2008-01-16 |
Orexigen Therapeutics Inc |
Methods of treating anxiety disorders
|
|
AR057946A1
(es)
|
2005-11-28 |
2007-12-26 |
Orexigen Therapeutics Inc |
Formulacion de zonisamida de liberacion sostenidda
|
|
WO2007084290A2
(en)
|
2006-01-12 |
2007-07-26 |
Orexigen Therapeutics, Inc. |
Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
|
|
EP1813276A1
(en)
|
2006-01-27 |
2007-08-01 |
Euro-Celtique S.A. |
Tamper resistant dosage forms
|
|
US8916195B2
(en)
*
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
|
EP2719378B1
(en)
|
2006-06-19 |
2016-08-31 |
Alpharma Pharmaceuticals LLC |
Pharmaceutical compositions
|
|
CA2693992C
(en)
|
2006-07-20 |
2017-01-31 |
Somaxon Pharmaceuticals, Inc. |
Methods of improving the pharmacokinetics of doxepin
|
|
US8682445B2
(en)
|
2006-07-28 |
2014-03-25 |
Cyberonics, Inc. |
Patient management system for treating depression using an implantable medical device
|
|
TW201811315A
(zh)
|
2006-11-09 |
2018-04-01 |
美商歐瑞根治療有限公司 |
層狀醫藥調配物
|
|
CA2668885C
(en)
|
2006-11-09 |
2016-08-02 |
Orexigen Therapeutics, Inc. |
Methods for administering weight loss medications
|
|
GB2447949B
(en)
|
2007-03-29 |
2010-03-31 |
Renasci Consultancy Ltd |
A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
|
|
RU2342195C1
(ru)
|
2007-04-18 |
2008-12-27 |
Институт проблем комплексного освоения недр РАН |
Устройство для механоактивации сульфидсодержащих минеральных продуктов
|
|
US8318813B2
(en)
|
2007-09-13 |
2012-11-27 |
Lcs Group, Llc |
Method of treating binge eating disorder
|
|
US8846053B2
(en)
|
2008-09-26 |
2014-09-30 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
|
EP2303025A4
(en)
|
2008-05-30 |
2012-07-04 |
Orexigen Therapeutics Inc |
METHOD FOR TREATING DIGITAL FAT SWITCHES
|
|
EP3659604A1
(en)
|
2010-01-11 |
2020-06-03 |
Nalpropion Pharmaceuticals, Inc. |
Methods of providing weight loss therapy in patients with major depression
|
|
US8492422B2
(en)
|
2010-09-16 |
2013-07-23 |
Allergan, Inc. |
Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
|
|
EP2642988A1
(en)
|
2010-11-26 |
2013-10-02 |
Ramot at Tel-Aviv University Ltd |
Method and composition for weight-gain management
|
|
TWI618536B
(zh)
|
2010-12-03 |
2018-03-21 |
歐瑞根治療有限公司 |
於納曲酮療法中增加藥物生物可利用性
|
|
US20130252995A1
(en)
|
2010-12-03 |
2013-09-26 |
Orexigen Therapeutics, Inc. |
Methods for reducing binge or compulsive eating
|
|
PT3730132T
(pt)
|
2012-06-06 |
2022-08-16 |
Nalpropion Pharmaceuticals Llc |
Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
|
|
US8969371B1
(en)
|
2013-12-06 |
2015-03-03 |
Orexigen Therapeutics, Inc. |
Compositions and methods for weight loss in at risk patient populations
|